新辅助化疗配合手术治疗中晚期乳腺癌的临床效果分析

目的:观察新辅助化疗配合手术治疗中晚期乳腺癌的临床效果,为临床研究提供参考。方法:选取我院2009年5月-2011年4月收治的中晚期乳腺癌患者107例,根据治疗方法的不同,将患者分为新辅助化疗组和对照组。新辅助化疗组采取术前辅助化疗,而对照组术前不接受化疗。观察新辅助化疗组患者的近期临床疗效、毒副反应发生率;比较两组患者的手术时间、术中出血量等;术后随访三年,记录两组患者的肿瘤局部复发率及远处转移率。结果:新辅助化疗组患者治疗的总有效率为79.66%,毒副反应的发生率为33.89%;新辅助化疗组的平均手术时间、术中出血量均低于对照组,差异具有统计学意义(P0.05)。新辅助化疗组患者的局部复发率为5.08%,远处转移率为6.78%;对照组患者局部复发率为12.50%,远处转移率为18.75%。新辅助化疗组患者的肿瘤复发转移率低于对照组,差异具有统计学意义(P0.05)。结论:在中晚期乳腺癌的临床治疗中,术前对患者实施新辅助化疗具有明显的效果,患者近期疗效良好,毒副反应可耐受,且手术后的复发转移率相对较低,值得推广应用。

Clinical Analysis of Neoadjuvant Chemotherapy Combined with Surgery for Patients with the Metaphase or Advanced Breast Cancer

Objective:To observe the clinical efficacy of the neoadjuvant chemotherapy on the treatment of metaphase or the advanced breast cancer in order to provide a reference for subsequent researches.Methods:107 patients with the metaphase or the advanced breast cancer who were treated in our hospital from May 2009 to April 2011 were selected and divided into the neoadjuvant group and the control group on the basis of different treatment methods. The patients in the neoadjuvant group were treated by the neoadjuvant chemotherapy before the surgery, while the patients in the control group were performed by the single surgery. Then the clinical effects and the incidence of adverse reactions of patients in the neoadjuvant group were evaluated; The operation time and the blood loss of patients in the two groups were observed and compared; The rate of recurrence and metastasis of patients in the two groups were recorded after a three-years'' follow-up.Results:The total effective rate was 79.66% and the incidence of adverse reactions was 33.89% in the neoadjuvant group; The operation time and the blood loss were less than those of the patients in the control group; The rates of recurrence and metastasis were 5.08% and 6.78% in the neoadjuvant group respectively, which were better than 12.50% and 18.75% of the patients in the control group with statistically significant differences (P<0.05).Conclusion:It is suggested that the neoadjuvant chemotherapy should be well promoted to assist the surgery for the treatment of the metaphase or the advanced breast cancer with the advantages of better clinical effects and lower incidence of adverse reactions.